There is a movement to rethink the design of clinical trials, with various approaches being considered. Some of these approaches include using bayesian methods, synthetic control arms, and patient-centric outcomes, and may apply to specific diseases such as multiple sclerosis, alzheimer's, and rare neurodegenerative diseases. The reevaluation of clinical trial design appears to be a broad effort, spanning multiple therapeutic areas and incorporating different methodologies.